Arcutis Biotherapeutics, Inc.
ARQT· Nasdaq
ARQTArcutis Biotherapeutics, Inc.
Filed Feb 22, 2022 · 10-K · 53 days after period end · 0001787306-22-000009
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|
| Net Income | -$71.33M | -$34.05M | -$12.57M |
| EPS Diluted | — | -$0.79 | -$6.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 22, 2022 · 53 d after period end
